{"success":true,"data":{"pressRelease":{"id":"158770","rtpr_id":"nPn3G4vDxa-20261001","ticker":"KPTI","exchange":"NASDAQ","all_tickers":["KPTI"],"title":"Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","author":"PR Newswire","published_at":"2026-10-01T20:05:00.436Z","article_body":"Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\nPR Newswire\n\nNEWTON, Mass., Oct. 1, 2026\n\nNEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc.\n(Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel\ncancer therapies, today announced that the Company granted 333 restricted\nstock units (RSUs) to one newly-hired employee. This RSU award was granted as\nof September 30, 2026 (the \"Grant Date\") pursuant to the Company's 2022\nInducement Stock Incentive Plan, as amended, as an inducement material to the\nnew employee entering into employment with Karyopharm in accordance with\nNasdaq Listing Rule 5635(c)(4).\n\nThe RSU award will vest over three years, with 33 1/3% of the shares\nunderlying the RSU award vesting on each of the three consecutive\nanniversaries of the Grant Date. The vesting of the RSU award is subject to\nthe employee's continued service as an employee of, or other service provider\nto, Karyopharm through the applicable vesting dates.\n\nAbout Karyopharm Therapeutics\n\nKaryopharm Therapeutics is a commercial-stage pharmaceutical company\npioneering the science of nuclear export inhibition to develop differentiated\ntherapies for patients with cancer. The Company's lead therapy, XPOVIO®\n(selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is\nmarketed by the Company in the U.S. for adults with relapsed or refractory\nmultiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50\nex-U.S. countries and territories. Building on its leadership in XPO1 biology,\nKaryopharm is advancing selinexor's potential in hematological cancers,\nincluding in myelofibrosis. The Company is also exploring opportunities to\nevaluate XPO1 inhibition across myeloproliferative neoplasms using\nnext-generation compounds, including eltanexor. Headquartered in Newton,\nMassachusetts, Karyopharm has an established, efficient, and scalable\ncommercial infrastructure to bring novel therapeutic options to patients with\ncancer. For more information, visit www.karyopharm.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786565-1&h=22774314&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4688567-1%26h%3D2095736339%26u%3Dhttp%253A%252F%252Fwww.karyopharm.com%252F%26a%3Dwww.karyopharm.com&a=www.karyopharm.com)\n and follow Karyopharm on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786565-1&h=1042853397&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4688567-1%26h%3D2855083057%26u%3Dhttps%253A%252F%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4685406-1%2526h%253D2147202234%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Fkaryopharm%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&a=LinkedIn)\n and on X at @Karyopharm.\n\nXPOVIO(®) and NEXPOVIO(®) are registered trademarks of Karyopharm\nTherapeutics Inc.\n\nCONTACT:\nBrendan Strong\nSenior Vice President, Investor Relations\n617.762.2661\nbrendan.strong@karyopharm.com (mailto:brendan.strong@karyopharm.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html\n(https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html)\n\nSOURCE Karyopharm Therapeutics Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS617852/Karyopharm-Therapeutics-Logo.jpg?id=OA2979783\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3G4vDxa-20261001","title":"Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","author":"PR Newswire","ticker":"KPTI","created":"2026-10-01T20:05:00.436Z","tickers":["KPTI"],"exchange":"NASDAQ","article_body":"Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\nPR Newswire\n\nNEWTON, Mass., Oct. 1, 2026\n\nNEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc.\n(Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel\ncancer therapies, today announced that the Company granted 333 restricted\nstock units (RSUs) to one newly-hired employee. This RSU award was granted as\nof September 30, 2026 (the \"Grant Date\") pursuant to the Company's 2022\nInducement Stock Incentive Plan, as amended, as an inducement material to the\nnew employee entering into employment with Karyopharm in accordance with\nNasdaq Listing Rule 5635(c)(4).\n\nThe RSU award will vest over three years, with 33 1/3% of the shares\nunderlying the RSU award vesting on each of the three consecutive\nanniversaries of the Grant Date. The vesting of the RSU award is subject to\nthe employee's continued service as an employee of, or other service provider\nto, Karyopharm through the applicable vesting dates.\n\nAbout Karyopharm Therapeutics\n\nKaryopharm Therapeutics is a commercial-stage pharmaceutical company\npioneering the science of nuclear export inhibition to develop differentiated\ntherapies for patients with cancer. The Company's lead therapy, XPOVIO®\n(selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is\nmarketed by the Company in the U.S. for adults with relapsed or refractory\nmultiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50\nex-U.S. countries and territories. Building on its leadership in XPO1 biology,\nKaryopharm is advancing selinexor's potential in hematological cancers,\nincluding in myelofibrosis. The Company is also exploring opportunities to\nevaluate XPO1 inhibition across myeloproliferative neoplasms using\nnext-generation compounds, including eltanexor. Headquartered in Newton,\nMassachusetts, Karyopharm has an established, efficient, and scalable\ncommercial infrastructure to bring novel therapeutic options to patients with\ncancer. For more information, visit www.karyopharm.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786565-1&h=22774314&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4688567-1%26h%3D2095736339%26u%3Dhttp%253A%252F%252Fwww.karyopharm.com%252F%26a%3Dwww.karyopharm.com&a=www.karyopharm.com)\n and follow Karyopharm on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786565-1&h=1042853397&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4688567-1%26h%3D2855083057%26u%3Dhttps%253A%252F%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4685406-1%2526h%253D2147202234%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Fkaryopharm%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&a=LinkedIn)\n and on X at @Karyopharm.\n\nXPOVIO(®) and NEXPOVIO(®) are registered trademarks of Karyopharm\nTherapeutics Inc.\n\nCONTACT:\nBrendan Strong\nSenior Vice President, Investor Relations\n617.762.2661\nbrendan.strong@karyopharm.com (mailto:brendan.strong@karyopharm.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html\n(https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html)\n\nSOURCE Karyopharm Therapeutics Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS617852/Karyopharm-Therapeutics-Logo.jpg?id=OA2979783\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-01T20:05:00.59901403Z","server_sent_at_ms":1790885100599},"received_at":"2026-10-01T20:05:00.650Z","source_url":"https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html"},"analysis":{"id":"147392","press_release_id":"158770","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Karyopharm Therapeutics granted 333 restricted stock units to one newly-hired employee under its 2022 Inducement Stock Incentive Plan.\n\nThe award, granted as of September 30, 2026, was made in accordance with Nasdaq Listing Rule 5635(c)(4) and vests over three years in equal annual installments.\n\nThis is a routine, boilerplate disclosure with no bearing on the company's clinical or commercial outlook.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant disclosure -- suppress."},"keyFigures":{"customDimensions":{"rsus_granted":333,"vesting_years":3}},"namedEntities":{"people":[{"name":"Brendan Strong","role":"Senior Vice President, Investor Relations"}],"products":["XPOVIO (selinexor)","NEXPOVIO","eltanexor"],"companies":[{"name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate disclosure of a small inducement equity grant (333 RSUs to one new hire) required under Nasdaq Listing Rule 5635(c)(4). No financial or operational impact."},"tickerRelevance":{"others":[],"primary":"KPTI"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"boilerplate-inducement-grant","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Karyopharm Therapeutics granted 333 restricted stock units to one newly-hired employee under its 2022 Inducement Stock Incentive Plan.\n\nThe award, granted as of September 30, 2026, was made in accordance with Nasdaq Listing Rule 5635(c)(4) and vests over three years in equal annual installments.\n\nThis is a routine, boilerplate disclosure with no bearing on the company's clinical or commercial outlook.","key_figures":{"customDimensions":{"rsus_granted":333,"vesting_years":3}},"named_entities":{"people":[{"name":"Brendan Strong","role":"Senior Vice President, Investor Relations"}],"products":["XPOVIO (selinexor)","NEXPOVIO","eltanexor"],"companies":[{"name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T20:05:09.829Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"boilerplate-inducement-grant","issuerAuthored":true}},"durationMs":3772,"modelName":"glm-5.3-flashx"}}